Search Results

Filter
  • 1-10 of  150 results for ""Dipeptidyl-Peptidase IV Inhibitors""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD.

  • Authors : Dahan M; Anxiety and Stress Research Unit, Ministry of Health, Beer-Sheva Mental Health Center, Beer-Sheva, Israel.; Department of Psychology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Subjects: Stress Disorders, Post-Traumatic*/Stress Disorders, Post-Traumatic*/Stress Disorders, Post-Traumatic*/drug therapy ; Stress Disorders, Post-Traumatic*/Stress Disorders, Post-Traumatic*/Stress Disorders, Post-Traumatic*/metabolism ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/pharmacology

  • Source: The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2024 Dec 01; Vol. 27 (12).Publisher: Oxford University Press Country of Publication: England NLM ID: 9815893 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.

  • Authors : Cordiner RLM; Division of Population, Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.; Bedair K

Subjects: Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/administration & dosage ; Blood Glucose*/Blood Glucose*/Blood Glucose*/drug effects ; Blood Glucose*/Blood Glucose*/Blood Glucose*/analysis

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Jul 12; Vol. 109 (8), pp. 2106-2115.Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited

Record details

×
Academic Journal

Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.

  • Authors : Fichadiya A; Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, T2N 4N1, Calgary, AB, Canada.; Quinn A

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Publisher: Oxford University Press Country of Publication: England NLM ID: 100883649 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.

  • Authors : Gao X; Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.; Zhang N

Subjects: Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Feb 23; Vol. 10 (2), pp. 103-117.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.

  • Authors : Wu MZ; Division of Cardiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518000, China.; Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 999077, China.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Jan 05; Vol. 10 (1), pp. 45-52.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Sodium-glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure.

  • Authors : Kanaoka K; Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.; Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.

Subjects: Acute Coronary Syndrome*/Acute Coronary Syndrome*/Acute Coronary Syndrome*/diagnosis ; Acute Coronary Syndrome*/Acute Coronary Syndrome*/Acute Coronary Syndrome*/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/adverse effects

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2023 Jul 29; Vol. 9 (5), pp. 444-452.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: evaluation of clinical course and treatment response.

  • Authors : Tzanani I; Department of Dermatology, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Israel.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/adverse effects

  • Source: Clinical and experimental dermatology [Clin Exp Dermatol] 2023 Jul 21; Vol. 48 (8), pp. 873-880.Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.

  • Authors : Wu T; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Wong CKH

Subjects: Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/surgery

  • Source: BJS open [BJS Open] 2023 Jul 10; Vol. 7 (4).Publisher: Oxford University Press Country of Publication: England NLM ID: 101722685 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.

  • Authors : Chan YH; The Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology

  • Source: European heart journal. Quality of care & clinical outcomes [Eur Heart J Qual Care Clin Outcomes] 2023 Jun 21; Vol. 9 (4), pp. 397-407.Publisher: Oxford University Press Country of Publication: England NLM ID: 101677796 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.

  • Authors : Lee HF; Division of Cardiology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City 23652, Taiwan.; The Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, Taoyuan City 33305, Taiwan.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/adverse effects

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2023 Jun 02; Vol. 9 (4), pp. 301-310.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

×
  • 1-10 of  150 results for ""Dipeptidyl-Peptidase IV Inhibitors""